Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.  CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   Google Scholar
• Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011;21(4):756–762. doi:10.1097/IGC.0b013e31821ce75d21543937
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–2529. doi:10.1056/NEJMra04184215590954
   PubMed Web of Science ®Google Scholar
• De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004;22(13):2635–2642. doi:10.1200/JCO.2004.09.08815226331
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98(15):1036–1045. doi:10.1093/jnci/djj29616882940
   PubMed Web of Science ®Google Scholar
• Pecorelli S, Favalli G, Gadducci A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009;27(28):4642–4648. doi:10.1200/JCO.2009.21.969119704064
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483. doi:10.1056/NEJMoa110439022204724
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496.22204725
   PubMed Web of Science ®Google Scholar
• Du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–3382. doi:10.1200/JCO.2014.55.734825225436
   PubMed Web of Science ®Google Scholar
• Meier W, Du Bois A, Rau J, et al. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol. 2012;126(2):236–240. doi:10.1016/j.ygyno.2012.04.05022564713
   PubMed Web of Science ®Google Scholar
• Korkmaz T, Seber S, Basaran G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials. Crit Rev Oncol Hematol. 2016;98:180–188. doi:10.1016/j.critrevonc.2015.10.00626603345
   PubMed Web of Science ®Google Scholar
• Qian X, Qin J, Pan S, Li X, Pan Y, Ma S. Maintenance therapy in ovarian cancer with targeted agents improves PFS and OS: a systematic review and meta-analysis. PLoS One. 2015;10(9):e0139026. doi:10.1371/journal.pone.011770226402447
   PubMed Web of Science ®Google Scholar
• Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130–137. doi:10.7326/0003-4819-159-2-201307160-0000823856683
   PubMed Web of Science ®Google Scholar
• Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80–97. doi:10.1002/jrsm.103726062083
   PubMed Web of Science ®Google Scholar
• Group G, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama. 2010;303(17):1729–1737. doi:10.1001/jama.2010.53420442389
   PubMed Web of Science ®Google Scholar
• van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple Myeloma. J Clin Oncol. 2017;35(12):1312–1319. doi:10.1200/JCO.2016.71.166328240968
   PubMed Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834.9921604
   PubMed Web of Science ®Google Scholar
• Gelman A, Rubin DB. Markov chain Monte Carlo methods in biostatistics. Stat Methods Med Res. 1996;5(4):339–355. doi:10.1177/0962280296005004029004377
   PubMedGoogle Scholar
• Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006;102(2):300–308. doi:10.1016/j.ygyno.2005.12.02016442153
   PubMed Web of Science ®Google Scholar
• Herzog TJ, Scambia G, Kim BG, et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol. 2013;130(1):25–30. doi:10.1016/j.ygyno.2013.04.01123591401
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study. J Clin Oncol. 2013;31(12):1554–1561. doi:10.1200/JCO.2012.46.405723478059
   PubMed Web of Science ®Google Scholar
• Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009;27(3):418–425. doi:10.1200/JCO.2008.17.840019075271
   PubMed Web of Science ®Google Scholar
• Vergote IB, Jimeno A, Joly F, et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and gynecologic cancer intergroup study. J Clin Oncol. 2014;32(4):320–326. doi:10.1200/JCO.2013.50.566924366937
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Thompson DS, Bismayer JA, et al. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. Cancer Med. 2015;4(5):673–681. doi:10.1002/cam4.37625556916
   PubMed Web of Science ®Google Scholar
• Vergote IB, Chekerov R, Amant F, et al. Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer. J Clin Oncol. 2013;31(25):3127–3132. doi:10.1200/JCO.2012.44.911623897968
   PubMed Web of Science ®Google Scholar
• Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol. 2009;36(2):112–125. doi:10.1053/j.seminoncol.2008.12.00319332246
   PubMed Web of Science ®Google Scholar
• Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122(1):89–94. doi:10.1016/j.ygyno.2011.03.01321529904
   PubMed Web of Science ®Google Scholar
• Mei L, Chen H, Wei DM, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev. 2013;29(6):CD007414.23813336
   PubMed Web of Science ®Google Scholar
• Bookman MA. Optimal primary therapy of ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i58–i62. doi:10.1093/annonc/mdw08827141074
   PubMed Web of Science ®Google Scholar
• Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov Med. 2010;9(44):62–70.20102688
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–1392. doi:10.1056/NEJMoa110553522452356
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164. doi:10.1056/NEJMoa161131027717299
   PubMed Web of Science ®Google Scholar
• Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936. doi:10.1016/S1470-2045(15)00086-826115797
   PubMed Web of Science ®Google Scholar
• Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer. 2011;21(4):750–755. doi:10.1097/IGC.0b013e31821b256821543936
   PubMed Web of Science ®Google Scholar